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Norwalk-like viruses (NLVs) are a diverse group of single-stranded, nonenveloped, positive-polarity RNA
viruses and are the leading cause of epidemic acute gastroenteritis in the United States. In this study, the major
capsid gene of Norwalk virus, the prototype NLV, has been cloned and expressed in mammalian cells using a
Venezuelan equine encephalitis (VEE) replicon expression system. Upon infection of baby hamster kidney
(BHK) cells with VEE replicon particles (VRPs), the Norwalk virus capsid proteins self-assemble to generate
high titers of Norwalk virus-like particles (VLPs) that are morphologically and antigenically analogous to
wild-type Norwalk virus. Mice inoculated subcutaneously with VRPs expressing the Norwalk virus capsid
protein (VRP-NV1) developed systemic and mucosal immune responses to Norwalk VLPs, as well as hetero-
typic antibody responses to the major capsid protein from another genogroup I NLV strain (NCFL) isolated
from a recent outbreak. A second Norwalk virus capsid clone (NV2) containing three amino acid codon
mutations from the NV1 clone was also expressed using VEE replicons (VRP-NV2), but upon infection of BHK
cells failed to confer VLP self-assembly. Mice inoculated with VRP-NV2 elicited reduced systemic and mucosal
immune responses to Norwalk VLPs, demonstrating the importance and potential utility of endogenous VLP
presentation for maximum immune induction. Inoculation with either VRP-NV1 or VRP-NV2 resulted in
serum antibody responses far superior to the induction in mice dosed orally with VLPs that were prepared
using the VEE-NV1 replicon construct, a regimen similar to current models for NLV vaccination. Expression
of NLV VLPs in mammalian cells offers a powerful approach for the design of novel NLV vaccines, either alone
or in combination with current vaccination models.
Norwalk-like viruses (NLVs) are the most frequent cause of
epidemic gastroenteritis in the United States, infecting an es-
timated 23 million people each year, and have accounted for as
much as 96% of selected outbreaks of acute, nonbacterial
gastroenteritis (20, 40, 47). Persons of all ages are affected, and
it is unclear whether infection typically confers long-term im-
munity (38). NLV outbreaks commonly occur within families,
nursing homes, day care centers, schools, hospitals, and in the
military (1, 20, 40, 42). Infection with NLVs usually results in
an episode of acute, self-limited gastroenteritis, with symptoms
rarely more serious than nausea, vomiting, diarrhea, and low-
grade fever (40), and most outbreaks are likely not reported
(47). However, using refined molecular detection methodolo-
gies, recent studies have extended the public health signifi-
cance of NLV infections and suggest that NLVs are a common
cause of severe diarrhea in children (22, 53). Although further
studies are necessary, NLVs may cause as much as 20% of
endemic diarrheal disease in family settings in developed coun-
tries (42).
The mortality attributable to NLV infection remains un-
clear, but fatalities among infected elderly may not be uncom-
mon. It has been suggested that NLV infections cause approx-
imately 50,000 hospitalizations and 310 deaths in the United
States each year (22, 47), although additional studies are
needed to elucidate the potential of NLVs for causing severe
disease. In developing countries, the overall extent of NLV-
associated disease burden remains to be resolved, but infection
can lead to malnutrition in young children and infants (53, 55).
An effective vaccine would be useful for health care providers,
food handlers, military personnel, and other at-risk popula-
tions to prevent the significant morbidity and potential mor-
tality associated with NLV infection (18, 45, 63).
Because no reliable tissue culture or animal model for NLV
infection is available to date, studies into the biology of NLVs
have relied on recombinant molecular approaches. NLVs are
classified as members of the family Caliciviridae. The genome
of Norwalk virus, the prototype NLV, consists of a positive-
sense, single-stranded RNA of approximately 7.5 kb in length
that is organized into three open reading frames (ORFs) (for
a recent review, see reference 11). ORF1 encodes the Norwalk
virus nonstructural proteins, including putative helicase, polio-
virus-like 3C-protease, and polymerase proteins (37). ORF2
and ORF3 encode structural proteins, with ORF2 encoding
the major capsid protein, and ORF3 encoding a minor struc-
tural protein assumed to associate with the capsid protein,
possibly to initiate encapsidation of the genome (21, 36).
Based on sequence homologies in regions of the polymerase
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and capsid genes, the genetically diverse NLVs can be divided
into GI and GII genogroups, with seven to eight clusters as-
signed to each genogroup (66). Isolates differ by 30% amino
acid identity in the major capsid protein within each geno-
group, and by more than 50% between isolates in different
genogroups (24). The extensive antigenic variability in the ma-
jor capsid protein of NLVs correlates with the typical lack of
heterotypic immune protection across NLV genogroups after
infection (reviewed in reference 46).
The most informative studies of Norwalk virus structure and
immunogenicity have stemmed from the production of recom-
binant baculoviruses expressing the Norwalk virus ORF2-en-
coded capsid protein, which upon infection of insect Sf9 cells
results in the expression and self-assembly of intact Norwalk
virus-like particles (Bac-Nor) (36). This accomplishment led to
the first NLV human vaccine trials (2). Oral inoculation of
Bac-Nor particles induces antigen-specific serum immunoglob-
ulin G (IgG) and mucosal IgA responses in mice and boosts
antibody levels in humans previously exposed to NLVs (2, 3).
A second novel method for NLV vaccine design followed these
experiments and used transgenic tobacco and potato plants to
express and deliver Norwalk virus capsid proteins after inges-
tion (44).
While these oral vaccine strategies mimic the natural route
of NLV infection, serum and mucosal immune responses to
Norwalk virus capsid proteins are modest and below the levels
exhibited after wild-type Norwalk virus infection (18, 45, 63).
Most recently it has been demonstrated that Bac-Nor could
induce similar levels of systemic and mucosal immune induc-
tion when administered to mice intranasally (27). It is not clear
whether these current vaccine approaches will elicit protective
immunity to Norwalk virus or protection against heterotypic
NLV strains. Additionally, although the baculovirus- and
plant-expressed virus-like particles (VLPs) appear to be mor-
phologically and antigenically identical to wild-type Norwalk
virus capsid proteins (25), it is important to consider possible
subtle differences attributable to posttranslational modification
patterns or protein folding in the nonmammalian versus mam-
malian cell systems. Based on these criteria, it is appropriate to
consider complementary approaches for NLV vaccine design.
Venezuelan equine encephalitis virus (VEE) and other al-
phaviruses have been studied extensively for their use as vec-
tors to express heterologous proteins, both in vitro and in vivo
(reviewed in references 61 and 65). The 5 two-thirds of the
VEE genome encodes nonstructural proteins required for
transcription and replication, whereas the 3 one-third encodes
structural proteins under the control of an internal 26S pro-
moter (39), a property that has been exploited for the produc-
tion of VEE replicons. The internal 26S promoter drives tran-
scription of downstream genes, generating subgenomic mRNAs
at concentrations nearly 10 times that of full-length genomic
RNAs, resulting in an abundance of protein production (61,
65).
Using cDNA clones, VEE replicons are constructed by re-
placing VEE structural genes with sequences encoding a pro-
tein(s) of interest. Cotransfection of baby hamster kidney
(BHK) cells with the replicon RNA and helper RNAs encod-
ing VEE structural genes, which package the replicon RNA,
results in the production and budding of VEE viral replicon
particles (VRPs) from the transfected cells. The ensuing VRPs
serve as one-hit, nonpackaging virus vectors that can deliver an
expression system to produce ample concentrations of the het-
erologous protein in a wide range of mammalian cell lines.
VEE replicons are currently being used for immunology, mo-
lecular, and cell biology research applications and are also a
promising new tool for the design of novel vaccines for human
use (16, 32, 61, 65).
We have recently demonstrated expression of large quanti-
ties of Norwalk VLPs in mammalian cells using a VEE repli-
con expression system (VRP-NV1) (Baric et al., submitted for
publication). To evaluate the potential utility of the VEE rep-
licon system for NLV vaccine design, three main objectives
were pursued with the experiments described in this paper: to
determine whether inoculation of mice with VRP-NV1 results
in systemic, mucosal, and/or heterotypic immune responses to
Norwalk VLPs; to compare the systemic and mucosal immune
responses in mice inoculated with VRP-NV1 with those in
mice inoculated with a second VRP construct (VRP-NV2),
which expresses Norwalk virus capsid proteins that do not
self-assemble into VLPs in vitro; and to compare the immune
responses in mice inoculated with either VRP construct with
those in mice orally inoculated with Norwalk VLPs, a regimen
similar to current NLV vaccine approaches.
Our results demonstrate that VEE replicons expressing in-
tact Norwalk VLPs induce the highest levels of systemic and
mucosal immune responses in mice compared with the other
tested vaccination regimens. Also, we observed that serum
antibody elicited in mice inoculated with VRP-NV1 cross-
reacts with the capsid protein from a heterotypic GI NLV
strain (NCFL) isolated from a recent outbreak that occurred
during a football game in North Carolina (4). The VEE-based
vaccination method described in this paper offers a powerful
complementary approach to current NLV vaccine strategies
and, as a model system, provides a useful technique for gen-
erating VLPs in mammalian cells for future applications be-
yond NLV research and vaccine design.
MATERIALS AND METHODS
Virus and cells. Norwalk virus antiserum and fecal specimens containing
Norwalk virus were obtained from a human challenge study with the Norwalk
virus NV8FIIa inoculum (Moe et al., unpublished data). The prechallenge im-
mune status and response in terms of serum antibody titers, virus shedding, and
clinical symptoms in all volunteers have been determined and will be described
in more detail elsewhere. The NCFL viral strain was obtained from a specimen
from a recent NLV outbreak that occurred during a football game in North
Carolina (4).
Baby hamster kidney (BHK) cells were maintained in MEM containing 7%
fetal clone II (HyClone Laboratories; Logan, Utah), 10% tryptose phosphate
broth, kanamycin (0.25 g/ml) and gentamicin (0.05 g/ml). Cultures were main-
tained at 37°C in a CO2 incubator.
Cloning and sequencing. NV1 and NV2 capsid clones were obtained by re-
verse transcription (RT)-PCR of high-titer Norwalk virus fecal samples from
NV8FIIa-infected volunteers as described (Baric et al., submitted). The NCFL
capsid clone was obtained by RT-PCR of RNA extracted from the stool of an
individual infected from a recent NLV outbreak (4). The NCFL capsid gene was
cloned using procedures for mRNA isolation from stool and PCR conditions
based on methods previously described for amplification of the NV2 capsid clone
(Baric et al., submitted). Briefly, mRNA was isolated from a 20% stool mixture
using an Oligotex Direct mRNA Minikit (Qiagen; Valencia, Calif.). RT reactions
were performed with a 5-l aliquot of the purified mRNA using Superscript II
reverse transcriptase (Invitrogen Life Technologies; Carlsbad, Calif.) according
to the manufacturers’ directions and either primer NW-550 (5-GTACAGCAT
ACACACAAG(A/G)CG-3) or NW-3AscI (GACATTCGGCGCGCCTTATC
GGCGCAGACCAAGCCTAC). PCRs designed to amplify the NCFL capsid
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gene by overlapping extension PCR were performed using an Expand Long
Template PCR system (Roche Molecular Biochemicals; Indianapolis, Ind.). Re-
action A amplified 550 bases of the 5 end of the NCFL capsid gene using the
primers NW-550 and VEE-NW5 (5-AGTCTAGTCCGCCAAGATGATGAT
GGCGTCTAAGGACGC-3). Reaction B amplified the region from bp 550 to
the 3 end of the ORF2 sequence using the primers NW-3AscI and NW  550
(GCG(C/T)CTTGTGTGTATGCTGTAC). An additional PCR using 1 l from
each of reactions A and B and the VEE-NW5 and NW-3AscI primers amplified
the full-length capsid. The 1.6-kb fragment was ligated overnight at 15°C into
the pGEM-T vector system (Promega; Madison, Wis.). One tenth of the ligation
reaction was transformed into competent Escherichia coli DH5 cells and plated
on YT/ampicillin/X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)/
isopropylthiogalactopyranoside (IPTG) plates, followed by selection and screen-
ing of white colonies. All NLV clones were confirmed by restriction digest and
sequence analyses.
Production of VEE replicon particles. The procedure for insertion of the NV1,
NV2, and NCFL capsid genes into the multicloning site of the VEE replicon
expression vector, pVR21, and subsequent production of VEE viral replicon
particles (VRPs) was adapted from a method previously described by Pushko et
al. for the production of influenza virus hemagglutinin (HA)-expressing VEE
replicons (57). Briefly, NV1, NV2, and NCFL capsid sequences were inserted
downstream of the 26S promoter of pVR21 by overlapping extension PCR, using
primers and conditions as described (Baric et al., submitted). Full-length T7
transcripts of linearized VEE replicon cDNAs encoding NV1, NV2, and NCFL
capsids were generated in vitro using an mMessage mMachine kit (Ambion;
Austin, Tex.) and mixed with two helper packaging mRNAs encoding the VEE
capsid and attenuated glycoprotein-3014 proteins (17). Transcripts were cotrans-
fected into BHK cells by electroporation of 800-l suspensions of 107 cells/ml in
phosphate-buffered saline (PBS) using three electrical pulses of 850 V at 25 F
with a Bio-Rad Gene Pulser II electroporator (Bio-Rad; Hercules, Calif.).
Electroporation efficiencies ranging from 60 to 80% were measured using
Sindbis virus replicon RNAs encoding green fluorescent protein (data not
shown) (Sindbis virus replicons kindly provided by Charles Rice; Rockefeller
University, New York, N.Y.). The transfected BHK cells were seeded into
75-cm2 flasks and incubated at 37°C for 36 h. VRPs were harvested 30 h post-
transfection from BHK cell supernatants and pelleted at 27,000 rpm for 3 h
(using a Beckman SW28 rotor) through a 20% sucrose cushion. The resulting
VRPs encoding NV1, NV2, or NCFL are, respectively, designated VRP-NV1,
VRP-NV2, and VRP-NCFL.
Production and harvesting of NLV virus-like particles. Flasks (75 or 175 cm2)
of BHK cells were infected with VRPs at a multiplicity of infection (MOI) of
approximately 2. At 33 to 36 h postinfection, the supernatants were collected and
centrifuged at 2,000  g to collect any nonadherent cells and cell debris, and the
pellets and cell monolayers were lysed by three freeze-thaw cycles. The super-
natants and lysed cell suspensions were clarified by centrifugation at 15,000  g
to remove cell debris, followed by ultracentrifugation at 27,000 rpm for 3 h
through a 20% sucrose cushion.
Electron microscopy (EM) analysis of putative Norwalk VLP (VEE-Nor)
suspensions was performed using a negative staining technique as described
(Baric et al., submitted). Protein concentrations were determined by protein
assay using bovine serum albumin (BSA) as a protein standard (Bio-Rad).
Immunofluorescence analysis. To monitor transfections and titer VRPs by
immunofluorescence analysis (IFA), BHK cells were grown on four- or eight-well
LabTek chamber slides (Nalge Nunc International; Naperville, Ill.), infected with
serially diluted VRP-NV1, VRP-NV2, or VRP-NCFL, and incubated in a 37°C
CO2 incubator. At 24 h postinfection, slides were fixed in acetone-methanol (1:1)
and stored at 4°C for at least 1 h. When examining transfected cells, approxi-
mately 105 electroporated cells were seeded onto four- or eight-well chamber
slides. The slides were incubated and fixed as described above. Fixed cells were
rehydrated in PBS (pH 7.2) and incubated with a 1:100 dilution (in PBS) of
appropriate antisera for 1 h at ambient temperature. After three washes in PBS,
a 1:100 dilution of either goat anti-human or goat anti-mouse IgG-fluorescein
isothiocyanate (FITC) conjugate (Sigma; St. Louis, Mo.) was added, and the
slide was incubated for 30 min at ambient temperature, followed by three addi-
tional PBS washes. Slides were examined and photographed under a Zeiss
LSM110 confocal fluorescent microscope. Images were digitized and assembled
using Photoshop 5.5 (Adobe Systems Inc.).
Mouse inoculations and sample collection. Four- to six-week-old male iso-
genic BALB/c mice were obtained from Charles River Laboratories (Wilming-
ton, Mass.), and all mice were maintained in the same environment and fed the
same diet. Mice for VRP-NV1, VRP-NV2, and oral dosing were analyzed in
groups of four, and groups of two mice were inoculated with either VRP-HA
(expressing influenza virus HA) or PBS as negative controls.
VRPs were inoculated by footpad injection, and 75-g suspensions of VEE-
Nor were administered by oral gavage according to the inoculation schedule
indicated in Table 1. Serum was obtained by tail bleed and collected in serum
separator tubes (Becton Dickinson Vacutainer Systems; Franklin Lakes, N.J.).
Fecal pellets obtained from all mouse groups were processed in the same man-
ner. Fresh pellets were obtained and immediately diluted 1:2 (wt/vol) in PBS
containing 0.1% Tween, 0.1 mg/ml thimerisol, and 0.1 mg/ml soybean trypsin
inhibitor (Sigma). Samples were then vortexed vigorously for 30 s, held on ice for
15 min, vortexed again, kept on ice for an additional 15 min, then finally vortexed
for 1 min. Samples were clarified twice by centrifugation at 10,000  g and
immediately stored at 70°C until tested. Prior to testing, thawed fecal extracts
were centrifuged at 10,000  g for 5 min to remove any additional particulate
matter.
Western blot analysis of Norwalk virus capsid proteins. Flasks of BHK cells at
90% confluence were infected with either VRP-NV1 or VRP-NV2 (in PBS
containing 1% fetal bovine serum) at an MOI of approximately 10 or mock
infected with dilution buffer. At 30 h postinfection, cells were collected using a
cell scraper and pelleted by centrifugation. After two washes with PBS, cell
pellets were resuspended in hot (80°C) sodium dodecyl sulfate (SDS) gel
loading buffer, boiled for 5 min, and clarified, and total cellular protein concen-
trations were determined by standard protein assay.
Samples were normalized to equivalent protein amounts and analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot using standard protocols (58). Gels were either stained with Coo-
massie brilliant blue or transferred to nitrocellulose blotting paper using a Bio-
Rad Transblot apparatus. Blots were blocked with 2% BSA in TBS-Tween
(0.05%) and probed with antiserum (1:1,000 in block solution) from a Norwalk
virus-infected volunteer. Antibody-reactive protein was visualized using a goat
anti-human IgG-alkaline phosphatase-conjugated secondary antibody (Sigma)
and 5-bromo-4-chloro-3-indolylphosphate (BCIP)/nitro blue tetrazolium (NBT)
substrate (Roche Molecular Biochemicals; Indianapolis, Ind.).
ELISA analysis. Serum and fecal extracts were analyzed by enzyme-linked
immunosorbent assay (ELISA) to detect antibodies to VEE-Nor. Briefly, 96-well
polyvinyl chloride (PVC) microtiter plates (Falcon 353911, Becton Dickinson)
were coated with 100 l of a 1-g/ml VEE-Nor solution in 0.05 M sodium
TABLE 1. Mouse inoculation schedule
Immunization group (n) Primary inoculum Route ofinoculationa Boost inoculum
Route of
inoculation Serum IgG (g/ml) (SD)
b Intestinal IgA (ng/ml) (SD)c
NV1:NV1 (4) VRP-NV1 FP VRP-NV1 FP 3506.7 (1277) 581.6 (331)
NV1:VEE-Nor (4) VRP-NV1 FP VEE-Nor Oral 377.1 (110) NR
VEE-Nor: VEE-Nor (4) VEE-Nor Oral VEE-Nor Oral 2.6 (3), 44.8d NR
NV2:NV2 (4) VRP-NV2 FP VRP-NV2 FP 303.1 (193) NR
PBS:PBS (2) PBS FP PBS FP NR N/A
HA:HA (2) VRP-HA FP VRP-HA FP 6.2e NR
a Footpad (FP) inoculations were with 10 l containing 107 infectious units of VRPs in sterile PBS or 10 l of PBS as a negative control; 75 g of VEE-Nor
suspensions in PBS was administered by oral gavage. VRP-HA expresses an influenza virus HA protein (15).
b Mean (standard deviation) VEE-Nor specific IgG for all mice on experimental day 44 as in Fig. 3. NR, no response detected.
c Mean (standard deviation) VEE-Nor specific IgA for all mice on experimental day 28 as in Fig. 4. N/A, not applicable, used to correct for background.
d Titer on day 28 from one mouse that responded to 200-g doses of VEE-Nor out of a total of four inoculated.
e Titer from one mouse obtained at this time point; the second did not respond.
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bicarbonate buffer, pH 9.6, for 4 h at ambient temperature. Plates were blocked
overnight at 4°C with 5% milk in PBS (5% Blotto) for serum analysis or blocked
in 10% Blotto for fecal extract analysis. Serum samples were diluted in 5% Blotto
based on a previously determined optical density (OD) linear range (1:50 min-
imum starting dilution for IgG, 1:20 for IgM), and fecal extract samples were
diluted 1:1 in 1% Blotto containing 0.5% fetal calf serum (FCS). Serum or fecal
samples were added to antigen-coated wells and twofold serially diluted. To
reduce the possibility of assay variation between mouse groups due to testing
conditions, fecal and serum samples from different groups were tested on the
same plates.
Samples were incubated at 37°C for 2 h, washed five times with PBS-Tween
(0.05%), followed by incubation with 100 l of either goat anti-mouse IgG
(1:5,000), IgM (1:5,000), or IgA (1:3,000) alkaline phosphatase-conjugated sec-
ondary antibodies (Sigma) in sample dilution buffer for 1 h at 37°C. Plates were
washed and developed with 150 l of p-nitrophenyl-phosphate (Sigma-FAST
tablets, Sigma), and the optical density (OD) at 405 nm was determined using an
ELISA plate reader (Molecular Devices; Sunnyvale, Calif.).
To quantitate serum IgG or IgM or fecal IgA titers, a standard curve was
created for each microtiter plate tested by coating a series of wells on the plate
with serially diluted, reagent-grade mouse IgG, IgM, or IgA standard (Sigma).
Data were analyzed using Softmax Pro software (Molecular Devices), and re-
sults, statistical analysis, and graphs were processed using Microsoft Excel. The
linear portion of each standard curve (R2  0.95) was used to calculate antibody
levels, and sample dilutions with ODs that fit in the standard curve were cor-
rected and averaged to generate standard units of VEE-Nor-specific serum IgG,
IgM, or fecal IgA units.
To correct for high background levels inherent in the intestinal IgA ELISA,
average IgA values obtained for each time point from mock-infected mice were
subtracted from corresponding time points for each mouse for all experimental
groups (average background for each time point 	 220 ng/l). Only individual
plate blanks (no primary antibody added) were used to correct for serum IgM
and IgG titers. Student’s paired and unpaired t tests were performed for statis-
tical analysis, with P 
 0.05 considered significant.
RESULTS
Cloning and expression of NLV capsid proteins from VEE
replicons. We previously cloned and sequenced the 1.6-kb
Norwalk virus ORF2 capsid genes, NV1 and NV2, from the
stools of NV8FIIa-infected human volunteers (Baric et al.,
submitted). The NV1 clone is identical to the wild-type Nor-
walk virus ORF2 amino acid sequence (M. Estes, personal
communication), whereas NV2 contains three amino acid vari-
ations from the wild-type sequence (Fig. 1a).
To study the induction of heterotypic immunity, a capsid
clone from a second GI NLV strain from a recent outbreak (4)
was cloned and sequenced (NCFL). The NCFL capsid protein
is nearly 99% identical in amino acid sequence to a GI.4 Chiba
reference strain (62), and approximately 72% identical to the
Norwalk virus capsid (Fig. 1a). All three NLV capsid genes
were inserted into the VEE replicon vector plasmid pVR21
(VEE-NV1, VEE-NV2, and VEE-NCFL, respectively). VEE
viral replicon particles of the NV1 and NV2 clones were gen-
erated by coelectroporating T7 transcripts of either VEE-NV1
or VEE-NV2 with transcripts of two helper plasmids encoding
the VEE capsid and attenuated 3014-glycoprotein genes. The
3014-glycoprotein variant confers increased heparan sulfate
attachment of VEE, resulting in an attenuated phenotype in
vivo (5, 17). The resulting VEE viral replicon particles were
harvested by ultracentrifugation through a 20% sucrose cush-
ion and titered by immunofluorescence analysis using anti-
serum from a Norwalk virus-infected volunteer (VRP-NV1
and VRP-NV2, respectively).
To characterize NCFL capsid protein expression from VEE,
BHK cells were electroporated with T7 transcripts encoding
VEE-NCFL and analyzed by IFA using antiserum from an
NCFL-infected patient (4). As controls for capsid protein ex-
pression, BHK cells were infected with either VRP-NV1 or
VRP-NV2 or mock infected with dilution buffer, followed by
IFA using Norwalk virus antiserum. IFA results clearly dem-
onstrated that all three NLV capsid proteins are expressed
from VEE and recognized by human antiserum, suggesting
that antigenic sites were retained in the NV1, NV2, and NCFL
capsid proteins (Fig. 2A).
Self-assembly of NLV virus-like particles. We previously
demonstrated that infection of BHK cells with VRP-NV1 but
not VRP-NV2 results in the production and self-assembly of
intact Norwalk VLPs (Baric et al., submitted). Similar results
are obtained after transfection of BHK cells with the respective
replicon RNAs, although it appears that relative levels of het-
erologous protein production are reduced compared with in-
fection with VRPs (data not shown).
Due to the potentially high levels of heterologous protein
expression from alphavirus replicons (61), we hypothesized
that the VRP-NV1 construct would produce high titers of
Norwalk VLPs that could be harvested and used for NLV
diagnostics and vaccine experiments. To evaluate the extent of
VLP production from VRP-NV1, flasks of BHK cells were
infected with either VRP-NV1 or VRP-NV2 as a negative
control at an MOI of 2 for 36 h. Cell monolayers were lysed
by freeze-thaw, and putative VLPs were collected by ultracen-
trifugation of clarified cell extracts through a sucrose cushion.
Transmission EM analysis confirmed that infection with VRP-
NV1 but not VRP-NV2 results in the self-assembly of Norwalk
VLPs (VEE-Nor) (Fig. 2B). Using latex beads as a standard,
VEE-Nor particle counts from VRP-NV1-infected BHK cells
were approximately 1010 particles per ml (data not shown).
Also, SDS-PAGE and Western analysis of purified VEE-Nor
demonstrated production of Norwalk virus capsid proteins of
the appropriate size, with no detectable background protein in
the preparations (data not shown).
We also evaluated whether VEE expression of the NCFL
capsid construct resulted in the production of VLPs. BHK cells
were transfected with T7 transcripts of VEE-NCFL, and cell
extracts were harvested for VLPs. Although IFA data demon-
strated NCFL capsid expression in replicon-transfected BHK
cells, EM analysis revealed that expression of NCFL did not
result in the self-assembly of intact VLPs (Fig. 2B), suggesting
the presence of certain debilitating amino acid codon muta-
tions in the NCFL clone that alter the capsid assembly cascade.
The Leu182Val, Ile333Val, and Val542Leu amino acid varia-
tions appear to be unique among several genetically similar GI
capsid proteins and were likely introduced by PCR amplifica-
tion (Fig. 1b and data not shown).
We hypothesized that potential folding differences between
the capsid protein expressed from VRP-NV2 versus VRP-
NV1, based on the inability to form intact VLPs, might render
the protein more susceptible to proteolytic degradation, which
may consequently alter its immunogenicity and presentation in
vivo. To test this hypothesis, crude extracts from VRP-NV1-
and VRP-NV2-infected BHK cells were analyzed by SDS-
PAGE and Western blot. Both constructs clearly expressed
Norwalk virus capsid proteins of the appropriate size that were
recognized by human antisera (Fig. 2C). However, an addi-
tional band of smaller size (30 kDa) was evident from the
VRP-NV2-infected cell extracts, suggesting that the lack of
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proper folding and/or assembly into intact VLPs results in
detectable proteolytic cleavage of the NV2 capsid protein.
Mouse inoculations. The availability of VEE VRPs and pu-
rified, high-titer VEE-Nor allows direct comparisons of im-
mune induction in response to a variety of NLV vaccine regi-
mens. We evaluated the immune induction in BALB/c mice
either subcutaneously inoculated with VEE VRPs expressing
Norwalk virus capsid proteins or orally dosed with VEE-Nor.
Isogenic BALB/c mice were inoculated and then boosted at
day 23 postinoculation by either footpad injection with VRPs
or oral dosing with VEE-Nor suspensions according to Table 1.
PBS and VRPs expressing influenza virus HA were injected
into mice as controls. We quantitated and compared the sys-
temic and mucosal immune induction in response to four dif-
ferent vaccination regimens and determined whether serum
antibody produced after inoculation with VRP-NV1 would
cross-react with the capsid protein from NCFL, a heterotypic
NLV strain. Compiled serum IgG and intestinal IgA data for
all mice on days 44 and 28, respectively, are included in Table
1.
Inoculation with VRP-NV1 induces serum IgM and IgG
responses to VEE-Nor in mice. VEE-Nor-specific serum IgM
and IgG induction in response to inoculation was quantitated
by ELISA. Mice immunized with VRP-NV1 (NV1:NV1) de-
veloped strong IgM titers after one inoculation (Fig. 3). The
average IgM titer was highest at the day 7 time point and
increased slightly after a second inoculation, although not as
profoundly as the initial response. IgM levels were negligible
by 21 days postboost, which is expected of a replicon-induced
immune response, as the VRPs infect only once without long-
term antigen production to stimulate continual IgM produc-
tion.
Immunization with VRP-NV1 also induced a strong serum
IgG response to VEE-Nor (Fig. 3). Even as early as day 7
postinoculation, IgG induction was detected in all four mice.
After a second inoculation, IgG titers increased by nearly 10-
FIG. 1. NLV capsid clones. NV1, NV2, and NCFL NLV capsid genes were cloned from fecal specimens and sequenced. NV1 and NV2 were
isolated from human volunteers infected with the NV8FIIa challenge inoculum (Moe et al., unpublished data), and NCFL was isolated from an
infected patient from a recent NLV outbreak that occurred during a football game in North Carolina (4). Amino acid variations and identities to
Chiba virus and Norwalk virus capsid (37, 62) are indicated in panel a. Panel b shows an amino acid alignment of NV1, NCFL, and Chiba capsids.
Differences from the Chiba reference are indicated in boldface. Note that the designated amino acid numbers in panel b might be shifted due to
the alignment.
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fold within 5 days, suggesting that repeat immunization with
VRPs can be used to substantially boost (P 
 0.01, Student’s
paired t test) antibody levels. IgG titers after the second inoc-
ulation continued to increase through the end of the experi-
ment, and the mean titer in serum samples taken at 121 days
postboost remained at more than 60% of the titer at 21 days
postboost (data not shown), demonstrating a robust, enduring
IgG response.
VRP-NV1 immunization induces the production of VEE-
Nor-specific mucosal IgA. Because NLVs are mucosal patho-
gens, it is likely that the ability to induce IgA responses at
mucosal surfaces will be a necessary feature of an effective
NLV vaccine (18). Therefore, we examined whether subcuta-
neous inoculation with VRP-NV1 results in the production of
antigen-specific mucosal IgA. To test the induction of a mu-
cosal response, buffered fecal extracts from immunized mice
were analyzed by ELISA for VEE-Nor-specific intestinal IgA.
Evaluation of intestinal IgA levels by fecal IgA quantitation
has been previously used to study mucosal immune induction
to both NLVs and Norwalk VLPs (3, 55). Although levels
FIG. 1—Continued.
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varied somewhat between mice, a single inoculation of VRP-
NV1 did not result in a significant increase (P  0.1, Student’s
paired t test) of detectable intestinal IgA by 14 or 21 days
postinoculation (Fig. 4). A second inoculation with VRP-NV1,
however, induced a significant increase (P 	 0.031) in intesti-
nal IgA in all four mice tested. These results suggest that
subcutaneous inoculation of VRP-NV1 stimulated the produc-
tion of VEE-Nor-specific IgA at mucosal surfaces in the diges-
tive tract, the likely site of NLV infection (40).
Systemic and mucosal immune responses after inoculation
with VRP-NV2 or oral inoculation of VEE-Nor particles. At
the same time mice were immunized with VRP-NV1, three
additional groups of mice were immunized with different reg-
imens to compare immune induction among all four NLV
vaccination strategies (Table 1). To determine whether the
potential for Norwalk VLP self-assembly might play a role in
eliciting immune responses to VEE-Nor, a group of four mice
were inoculated and boosted with VRP-NV2 (NV2:NV2), a
construct that expresses Norwalk virus capsid proteins that fail
to self-assemble into VLPs in vitro (Fig. 2). All mice inoculated
with VRP-NV2 developed serum IgM and IgG responses to
VEE-Nor, although IgG levels were considerably reduced
compared with mice inoculated with VRP-NV1, especially af-
ter the second inoculation (P 	 0.009 at day 28, Student’s t
test) (Fig. 3).
Even more remarkable was the difference in intestinal IgA
titers. Although one of the mice might have initially responded
by day 14 postinoculation, immunization with VRP-NV2 did
not result in significant levels (P  0.1) of detectable intestinal
IgA production at any time point tested (Fig. 4). These results
suggest that the potential for Norwalk VLP self-assembly likely
plays an important role for maximum immune induction to
VEE-Nor after VRP inoculation.
The NV1:VEE-Nor regimen was designed to determine if
FIG. 2. Expression and self-assembly of NLV capsid proteins. BHK cells were either infected with VEE VRPs expressing NV1 or NV2, mock
infected, or transfected with VEE replicon RNA expressing the NCFL capsid gene. (A) IFA for NV1, NV2, and NCFL capsid protein expression.
Cells were examined in a fluorescent microscope for NLV capsid expression using human antiserum to either Norwalk virus (NV1, NV2, and
Mock) or the NCFL isolate (NCFL) and goat anti-human IgG-FITC-conjugated secondary antibody. (B) BHK cell lysates were examined for
evidence of NLV VLP self-assembly. Putative VLPs were collected by ultracentrifugation through sucrose gradients and analyzed by negative-stain
electron microscopy. Scale bar, 100 nm. (C) NV1 and NV2 capsid proteins from VRP-infected BHK cell lysates were analyzed by Western blot
using human antiserum to Norwalk virus. Lanes marked 1x and 2x represent uninfected BHK cell lysates at 1 and 2 times the total loaded protein,
respectively, versus the NV1 and NV2 lanes. Arrows indicate Norwalk virus antiserum-reactive protein bands, and arrowheads indicate background
bands.
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oral inoculation with VEE-Nor can boost antibody responses
in mice previously exposed to VRP-NV1. Evaluation of serum
IgG results reveals a slight boost in serum IgG was evident
after a 75-g oral dose of VEE-Nor (Fig. 5). Statistical analysis
of raw data indicates that IgG levels did not increase signifi-
cantly (P  0.1, Student’s paired t test) from day 14 to day 21,
whereas VEE-Nor dosing on day 23 resulted in a significant
increase (P 
 0.01) in serum IgG titers from day 21 to day 28.
These data suggest that antibodies produced after VRP-NV1
inoculation recognized VEE-Nor in the digestive tract, result-
ing in a slight boost in serum IgG titers within 5 days after
VEE-Nor dosing. However, oral boosting with VEE-Nor did
not result in significant (P  0.1) detectable levels of intestinal
IgA (Fig. 4), suggesting that additional inoculations and/or
higher doses of VEE-Nor are likely needed to induce consid-
erable production of intestinal IgA after priming with VRP-
NV1.
A group of four mice were immunized and boosted orally
with 75 g of VEE-Nor particles (VEE-Nor:VEE-Nor), a reg-
imen that was designed to compare the VRP-based method to
an NLV oral vaccination strategy previously tested in mice and
humans (2, 3). Although modest serum IgM titers were elicited
after oral immunization with VEE-Nor, no serum IgG re-
sponse was notable (Fig. 3). Also, one or two oral inoculations
of VEE-Nor did not stimulate the production of intestinal IgA
above background levels of detection (P  0.1, Student’s t test)
at any time point (Fig. 4). Ball et al. demonstrated that mice
orally dosed with 75 g of baculovirus-expressed, recombinant
Norwalk VLPs (Bac-Nor) in the absence of adjuvant produced
limited serum antibody responses, whereas more consistent
responses were detected in mice dosed with at least 200 g of
Bac-Nor (3). Therefore, an additional four mice were similarly
inoculated and boosted with 200 g of purified VEE-Nor,
resulting in IgG induction in only one mouse, with a titer more
FIG. 3. Serum immune responses to Norwalk VLPs (VEE-Nor). Groups of four mice were inoculated on days 0 and 23 (indicated by arrows
in IgG chart) according to Table 1. Serum samples were collected and analyzed by ELISA for VEE-Nor-specific serum IgM or IgG. Experimental
regimens and sample time points are indicated. Error bars at each time point represent the standard deviation between mice. , three of four mice
represented; one mouse developed IgM levels nearly 10 times the average of the other three mice at this time point (data not shown). Data from
this mouse are included for all remaining time points.
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than 6- or 30-fold lower than the average response at the same
time point after VRP-NV2 or VRP-NV1 inoculation, respec-
tively (Table 1).
Heterotypic immune response. Due to extensive sequence
and antigenic variation among NLVs, an effective vaccine reg-
imen should provide cross-protective immunity to a variety of
GI and GII NLV strains. To test heterotypic immune induc-
tion, we determined whether serum from mice immunized with
VRP-NV1 could cross-react with the capsid protein from
NCFL, a heterotypic GI NLV strain isolated and characterized
from a recent outbreak (4). BHK cells were transfected with
RNA transcripts of a VEE replicon expressing the NCFL cap-
sid and seeded onto slides. The presence of heterotypic serum
IgG from VRP-NV1-inoculated mice (serum day 44 from Fig.
3) as well as from a Norwalk virus-infected human volunteer
was evaluated by IFA (Fig. 6).
The results demonstrate that mice inoculated with VRP-
NV1 as well as the individual infected with live Norwalk virus
develop serum IgG that cross-reacts with the capsid protein
from NCFL. The level of heterotypic IgG reactivity appears
similar in both the immunized mice and the infected volunteer
at the dilutions tested, but the significance of the signal simi-
larity cannot be established using this assay because different
FITC-conjugated secondary antibodies were used. Neverthe-
less, the overall signal was clearly reduced compared with the
reactivity of the homotypic NCFL antiserum. Although these
results do not demonstrate cross-protective immunity, the po-
tential for heterotypic immune induction in response to VRP
inoculation further establishes the VEE replicon system as a
practical approach to NLV vaccine design and warrants further
study to determine the extent of cross-reactivity to a variety of
GI and GII NLVs.
DISCUSSION
The most promising NLV vaccine designs currently being
pursued are based on oral inoculation of NLV VLPs expressed
from recombinant baculoviruses. There are several valuable
features of this vaccination approach, including simple oral
delivery of antigens, stability of the VLPs at various tempera-
tures for ease in transport, and presentation of antigens at the
sites of NLV infection (reviewed in reference 18). A recent
phase I clinical trial established that baculovirus-expressed,
recombinant Norwalk VLPs were safe in humans and induced
dose-dependent increases in antigen-specific serum IgG titers
in volunteers with existing serum IgG to Norwalk virus (2).
However, mucosal immune responses were not evaluated in
these individuals, and serum immune responses were inferior
to those elicited after live viral infection (2, 45).
Possible reasons for the lack of a vigorous IgG response to
orally dosed Norwalk VLPs include insufficient amounts of
antigen, lack of virus replication or amplification, inadequate
responses to antigen without the use of adjuvant, and the
possibility of tolerance induction. Guerrero et al. have recently
demonstrated that mice inoculated intranasally with Norwalk
VLPs generate systemic and mucosal antibody responses (27).
One major advantage of this vaccination strategy is that only
about one-tenth of the amount of VLPs is needed to induce
responses that are equivalent to, if not better than, those elic-
ited after oral inoculation.
With either inoculation method, the addition of adjuvant
greatly enhances and prolongs the systemic and mucosal re-
sponses (3, 27). However, it is not clear whether intranasal or
oral inoculation with Norwalk VLPs, let alone infection with
wild-type NLVs, confers long-term protective homotypic or
heterotypic immunity. Consequently, additional experiments
are needed to evaluate the efficacy of these mucosal vaccina-
tion methods. This paper describes a novel complementary
NLV vaccine approach employing an alphavirus-based expres-
sion method to generate NLV VLPs in a mammalian system.
Using a VEE replicon expression system, we have shown
FIG. 4. Intestinal IgA responses to VEE-Nor. Fecal pellets were
collected from all mice in each mouse group at the indicated time
points, processed to obtain a clarified, buffered extract, and analyzed
by ELISA. Samples are from the same mice inoculated on days 0 and
23 represented in Table 1 and Fig. 3. To correct for background, IgA
values for each time point from mock-infected mice were subtracted
from corresponding time points for all experimental groups.
FIG. 5. Serum IgG boost responses from NV1:VEE-Nor mice. Av-
erage serum IgG titers of four mice on days 14, 21, and 28, which were
inoculated on day 0 with VRP-NV1 and boosted orally on day 23
(arrow) with 75 g of VEE-Nor. Error bars represent standard devi-
ation. , the increase in IgG titers from day 14 to day 21 was not
statistically significant (P  0.1); , significant increase in IgG titers
from day 21 to day 28 (P 
 0.01; Student’s paired t test of data from
two separate ELISA analyses).
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that NLV capsid proteins self-assemble to generate large quan-
tities of NLV VLPs in mammalian cells. Importantly, as a
potential vaccine approach, and unlike mucosal or parenteral
inoculation of VLPs, VEE expression of the Norwalk virus
capsid protein provides a method for introducing endogenous
NLV VLPs into mammalian cells in a way similar to a natural
viral infection. Mice inoculated with VEE VRPs expressing
Norwalk virus capsid proteins developed significant serum and
mucosal immune responses to VEE-Nor, the strength of which
correlates with the ability of the expressed proteins to self-
assemble into VLPs. Serum IgG and IgM responses to VEE-
Nor after immunization with VRP-NV1 rose to remarkably
high levels, even after a single inoculation. VRP-NV1-immu-
nized mice also generated intestinal IgA responses, a feature
that is likely to be essential for protective immunity to NLV
infection.
The presence of cross-reactive IgG to a different GI NLV
capsid protein evokes the potential for heterotypic immune
induction, and these data represent the first known demonstra-
tion of a cross-reactive antibody response induced in mice with
a candidate NLV vaccine. Heterotypic immune induction will
likely be a necessary feature of an effective vaccine regimen
against the many genetically diverse NLV strains. Our results
suggest that a VEE-based vaccine provides a powerful com-
plementary approach to current NLV vaccine strategies.
We expect even greater heterotypic reactivity to NLV capsid
proteins that assemble into intact VLPs, which are more likely
to retain conserved conformational antigenic sites. Epitope
mapping of baculovirus-expressed Norwalk VLPs using a panel
of monoclonal antibodies has suggested that most antigenic
epitopes of the Norwalk virus capsid protein are in fact dis-
continuous and therefore likely to be present only in at least
partially assembled VLPs (28). Based on sequence data and
primer design, the noted variations in the NCFL clone at
amino acids 182, 333, and 542 were likely introduced by PCR.
Interestingly, amino acids 182 and 333 map to -strand and
dimerization sites, respectively, in the Norwalk virus capsid
crystal structure (54), and we therefore speculate that these
mutations were debilitating to the capsid assembly cascade.
Although the responses observed in mice orally inoculated
with VEE-Nor generally appear to be consistent with previous
experiments described by Ball et al. (3), certain discrepancies
exist between the results. In particular, mice orally dosed twice
with 200 g of Bac-Nor without adjuvant exhibited more con-
sistent serum immune responses than we could detect after two
200-g VEE-Nor doses (3). These differences might be attrib-
uted to the use of different mouse strains for inoculation,
differences in the purity of VEE-Nor and Bac-Nor antigen
preparations for animal dosing, and/or variability in ELISA
detection sensitivity. Despite these potential discrepancies, our
immunization and detection methods revealed that mice inoc-
ulated twice with VRP-NV1 developed considerably stronger
serum and intestinal immune responses than those given two
doses of either 75 or 200 g of VEE-Nor particles.
The fact that subcutaneous inoculation of VEE VRPs re-
sulted in the production of mucosal antibody is a conundrum
to conventional perception of mucosal immune induction. One
would expect that only immunization with live virus that can
disseminate to mucosal tissues, or the use of a mucosal route of
immunization, might result in a significant mucosal immune
response. VRPs are designed to infect for only one round of
replication and expression without packaging and spreading to
neighboring cells (57). Therefore, it is not immediately antic-
ipated that this vaccination strategy would be useful in stimu-
lating protective immunity against a mucosal pathogen. How-
ever, our data demonstrate that antigen-specific IgA, the
predominant antibody at mucosal surfaces, was present in the
digestive tract of VRP-NV1-immunized mice. We expect the
IgA present in fecal extracts from VRP-NV1-inoculated mice
arose from antibody-secreting cells in lymphoid tissue of the
gut, although this has not yet been confirmed.
Recent experiments have revealed that mice subcutaneously
inoculated with VRP-HA develop antigen-specific IgA-secret-
ing B cells in the gut and are protected against mucosal influ-
enza virus challenge (57; E. Richmond, personal communica-
tion). Other groups have similarly observed mucosal immune
responses after parenteral inoculation with nucleic acid or pro-
tein subunit vaccines (48, 50). The precise mechanism(s) for
mucosal immune induction after parenteral inoculation with a
nondisseminating vaccine is not known. Possible mechanisms
that we are currently addressing with the VEE replicon system
include the ideas that VRP-infected cells traffic to and present
antigen at mucosal inductive sites and VEE VRPs infect cells
in the draining lymph node, subsequently rendering the organ
into a mucosal inductive site.
The VEE-NV1 vaccination system described in this paper
may provide a valuable model for the study of replicon-in-
duced mucosal immunity. Because a human challenge model
for Norwalk virus infection is available, the use of VEE VRPs
expressing NLV capsid proteins might provide a powerful tool
FIG. 6. Heterotypic immune responses from VRP-NV1-inoculated mice. BHK cells were electroporated with NCFL-encoding VEE replicon
RNA, and cross-reactive IgG responses were examined by IFA. Reactivity was detected using (A) serum from an NCFL-infected patient, (B) serum
from a Norwalk virus-infected volunteer, (C) pooled high-titer serum from VRP-NV1-inoculated mice, and (D) preimmune mouse serum, followed
with goat anti-human or goat anti-mouse IgG-FITC-conjugated secondary antibodies.
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for the study of mucosal immunity in humans. This model
system would likely benefit researchers of a wide range of
animal and human mucosal pathogens.
Several groups have reported enhanced mucosal and sys-
temic immune responses using various combination mucosal/
parenteral immunization regimens (reviewed in reference 50).
Although the mucosal responses in mice primed with VRP-
NV1 could not be detectably enhanced after oral dosing with
75 g of VEE-Nor, we speculate that a combination prime-
boost immunization strategy will induce a more effective sys-
temic and mucosal immune response. In particular, we are
interested in evaluating responses in mice immunized with a
combination of parenterally administered VEE VRPs and in-
tranasally administered VEE-Nor. Also, wild-type VEE will
infect mice when administered intranasally (10, 14, 30, 31).
Therefore, it seems appropriate to explore the efficacy of an
intranasal VEE VRP inoculation as a means to enhance sys-
temic and mucosal immune responses to NLV capsid proteins.
Specific requirements for protective immunity against NLV
infection are not well established, with much of the available
data being contradictory. Limited data obtained prior to the
advent of recent molecular-based approaches to study NLV
immunity have suggested that existing serum antibody to NLVs
correlates with an increased risk of infection, while others have
demonstrated short-term and occasionally long-term immunity
to homologous rechallenge of NLV-dosed volunteers, as well
as natural immunity to NLV infection upon repeated exposure
within communities (reviewed in references 18 and 40). Long-
er-term immunity to NLV infection likely requires a mucosal
response to localized areas of infection. The fact that no small-
animal or tissue culture system is available to cultivate NLVs
makes it difficult to identify important components of a pro-
tective immune response. The development of such systems
and the design of innovative human challenge experiments are
needed to fully address NLV infectivity and pathogenesis and
to assay the effectiveness of candidate NLV vaccines.
VEE replicon systems have been used to design vaccines
that induce systemic, mucosal, and cellular immune responses
to heterologous viral proteins (9, 10, 15). Several VEE replicon
vaccine regimens to date have been shown to be safe in a wide
range of laboratory animals and provide mucosal and/or sys-
temic protection against a number of viral pathogens, including
influenza, Ebola, Marburg, and simian immunodeficiency vi-
ruses (16, 32, 56, 57). Also, immunity induced in mice by
sequential immunization with distinct VRP constructs has con-
firmed the effectiveness of VEE-based vaccines for repeat im-
munizations against different viral pathogens (57).
A significant advantage of the VEE replicon vaccination
system is the fact that VEE viruses naturally target profes-
sional antigen-presenting cells, particularly dendritic cells (15),
which are potent stimulators of T-cell responses to virus-in-
fected cells (34). As a result, VEE replicons stimulate high
levels of antigen-specific, cytotoxic T lymphocytes (8, 9), which
often play an important role in providing protective immunity
against viral infection. To our knowledge, cellular immunity to
NLV infection has not been examined. Therefore, the role of
cellular immunity in protection against NLV infection is un-
known. We are currently investigating the cytotoxic T-lympho-
cyte response to NLV capsid proteins in humans infected with
NLVs, as well as in mice immunized with VEE VRPs.
VLP-based vaccines not only allow the ability to present
conformational antigens that are morphologically and immu-
nologically analogous to live virus counterparts, but also allow
the presentation of viral antigens that are likely more resistant
to proteolytic degradation (such as in the digestive tract) (3,
29). The additional lower-molecular-weight protein product
observed from VRP-NV2-infected BHK cells is of particular
interest (Fig. 2C). We hypothesize that it represents a Norwalk
virus capsid protein cleavage product similar to those found in
the stools of Norwalk virus-infected patients, as well as from
protease-treated, baculovirus-expressed Norwalk VLPs (26,
29). This hypothesis would explain why the product is not
detected from cells infected with VRP-NV1, which expresses
capsid proteins that self-assemble into intact VLPs. Similarly,
alkaline dissociation of baculovirus-expressed Norwalk VLPs
exposes a trypsin cleavage site that is otherwise protected in
fully assembled particles (69). Consequently, we cannot rule
out the possibility that reduced immune responses after immu-
nization with VRP-NV2 versus VRP-NV1 are the result of less
full-size capsid protein present in VRP-NV2-infected cells of
immunized mice. However, it is more likely that the presence
of fully assembled VEE-Nor particles provides additional con-
formational and discontinuous epitopes that are not present in
the full-length, unassembled capsid proteins.
VLPs are currently being examined for vaccine purposes for
a number of other human pathogens, including rotavirus, pap-
illomavirus, polyomavirus, and human immunodeficiency virus
(HIV) (12, 23, 60, 67). A variety of vectors have been used to
express VLPs, including vaccinia viruses, baculoviruses, alpha-
viruses, yeasts, and bacteria, among others (6, 49, 59).
Unlike soluble subunit counterpart vaccines, Pr55gag-based
HIV VLPs have been shown to induce high titers of HIV-
specific antibodies without the use of adjuvant (68). Also, de-
naturation of human papillomavirus VLPs prior to immuniza-
tion abolishes the ability of the vaccine to induce protective
immune responses in animal models (7, 41). VLPs also offer a
greater possibility to induce cross-protective immunity, as mice
vaccinated with rotavirus VLPs are protected from challenge
with heterotypic strains (13, 35). These experiments clearly
demonstrate the importance of authentic conformational
epitopes that can only be presented on VLPs and live virions to
elicit maximum levels of virus-neutralizing antibodies.
It is important to consider the potential for certain dissimi-
larities in VLPs attributable to nonmammalian expression, as
the proteins might be posttranslationally processed in a differ-
ent manner in mammalian and insect cell expression systems.
Although we have not observed any differences between bac-
ulovirus and VEE-expressed Norwalk VLPs (Baric et al., sub-
mitted), previous experiments have demonstrated subtle vari-
ations between insect and mammalian posttranslational
modification patterns of recombinant proteins (33, 64). For
example, baculovirus- and vaccinia virus-expressed papilloma-
virus VLPs were recently shown to possess notable variations
in phosphorylation and glycosylation properties (19). Such
variations attributable to insect cell expression might be ex-
tremely important, as posttranslational modifications have
been shown to play a vital role in the immunogenic manifes-
tation of recombinant proteins, especially notable for cytotoxic
T-lymphocyte induction (43, 51, 52).
As a model system, the VEE-based approach described in
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this paper represents an advantageous method for the expres-
sion of heterologous proteins in a more natural cellular envi-
ronment, which will likely increase the chances of generating
biologically authentic proteins for vaccine purposes. In addi-
tion, since VEE replicons do not reassemble after infection,
this method provides a means for producing high-titer VLPs in
the absence of contaminating helper virus. VEE-based expres-
sion of VLPs might also prove useful for researchers studying
other viruses, as structural proteins from many viruses can be
expressed to generate VLPs.
Because NLVs have not been successfully cultured in vitro,
little is known about the expression, subcellular location, and
processing of NLV capsid proteins. Systems for the expression
and self-assembly of NLV capsid proteins in mammalian cells
are needed to fully understand NLV replication and pathogen-
esis. We believe that VEE replicon-driven Norwalk virus cap-
sid self-assembly will offer new insights into NLV entry, assem-
bly, encapsidation, and release and allow potential reverse
genetic approaches to recover infectious NLV particles from
mammalian cells. VEE replicons shall provide a complemen-
tary approach to baculovirus expression systems for studying
calicivirus molecular biology and pathogenesis and will likely
provide useful diagnostic tools for future NLV research.
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